Clinical trial
Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic…
NCT00457509 · Sanofi Pasteur, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00457509 |
|---|---|
| Title | Safety and Immunogenicity of H5N1 Adjuvanted, Inactivated, Split-Virion Pandemic Influenza Vaccine in Healthy Adults |
| Lead sponsor | Sanofi Pasteur, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pandemic Influenza, Influenza A Virus Infection, Orthomyxoviridae Infections |
| Intervention type | Biological |
| Interventions | A/H5N1 inactivated, split-virion influenza vaccine+Adjuvant, split-virion influenza vaccine |
| Enrollment | 251 |
| Start date | Jan 1, 2007 |
| Primary completion | Nov 1, 2009 |
| Completion | Sep 1, 2010 |
| First posted | Apr 6, 2007 |
| Last update posted | Jan 14, 2014 |
| Countries | Belgium |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: